WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
05 June 2017
Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
30 May 2017
Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds
13 April 2017
The first overall survival data from the Phase 3 CheckMate -067 clinical trial
03 April 2017
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute announce collaboration to accelerate immuno-oncology research
28 March 2017
Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL
02 March 2017
Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON)
27 February 2017
Bristol-Myers Squibb appoints three new independent directors
21 February 2017
Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results
26 January 2017
Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaboration
10 January 2017
Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen
05 January 2017
Bristol-Myers Squibb signs exclusive worldwide license agreement with PsiOxus Therapeutics
20 December 2016
Bristol-Myers Squibb strengthens capabilities with evolution of its U.S. geographic footprint
13 December 2016
Bristol-Myers Squibb reports third quarter results
27 October 2016
Bristol-Myers Squibb Foundation joins White House Cancer Moonshot
18 October 2016
Bristol-Myers Squibb and Nektar Therapeutics announce oncology clinical collaboration to evaluate the combination of Opdivo (nivolumab) and NKTR-214
27 September 2016
Bristol-Myers Squibb awards first "Golden Tickets" for LabCentral to PanTher, Suono Bio
20 September 2016
Bristol-Myers Squibb employees cycle Coast to Coast to raise money and awareness for cancer research
07 September 2016
Bristol-Myers Squibb reports second quarter financial results
29 July 2016
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
05 July 2016
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Research & Development
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Engineered bacteria find tumors, then alert the authorities
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
Bristol-Myers Squibb